Article
The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
Health technology assessment (Winchester, England) - 1 Oct 2014
Hartwell Debbie, Cooper Keith, Frampton Geoff K, Baxter Louise, Loveman Emma
Abstract excerpt
BACKGROUND: Optimal therapy for children with chronic hepatitis C is unclear. Two treatment regimens are currently licensed in children. OBJECTIVES: To assess the clinical effectiveness and cost-effectiveness of peginterferon alfa-2a (Pegasys®, Roche) and peginterferon alfa-2b [ViraferonPeg®, Merck Sharp & Dohme (MSD)] in combination with ribavirin (RBV), within their licensed indications, for the treatment of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.